Exelixis is making solid progress toward that goal. Late last year, it submitted an application to the U.S. Food and Drug ...

Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular ...

Kazia stated that in murine triple-negative breast cancer preclinical models, NDL2 reduced primary tumor volume by 49% as ...

Summit Therapeutics nears a 2026 FDA decision for ivonescimab with $710M cash and Akesobio catalysts. Find out why SMMT stock is upgraded to hold.

Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression SYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), an ...

Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.

A new study published in the International Journal of Molecular Sciences by researchers from the Georgia Institute of Cannabis Research at Augusta University found that inhaling cannabidiol (CBD) ...

The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to include ...

Media ReleaseEntered into strategic collaboration with Dr. Reddy’s for commercialisation of eftilagimod alfa (efti) in all countries outside ...

QureBio Ltd., a clinical-stage biotech company focusing on development of bispecific antibodies and other engineered ...

With 2026 set to be a banner year for M&A as buyers facing patent cliffs compete for a limited pool of late-stage assets ( [3]) , companies demonstrating disciplined pivotal execution and FDA ...

Cancer immunotherapy has transformed modern oncology by harnessing the body's own immune system to combat malignant disease.